• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥马韦洛酮(RTA408)对具有线粒体缺陷的原代成纤维细胞的可变效应。

Variable effects of omaveloxolone (RTA408) on primary fibroblasts with mitochondrial defects.

作者信息

Zighan Madleen, Arkadir David, Douiev Liza, Keller Guy, Miller Chaya, Saada Ann

机构信息

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Department of Neurology, Hadassah Medical Center, Jerusalem, Israel.

出版信息

Front Mol Biosci. 2022 Aug 12;9:890653. doi: 10.3389/fmolb.2022.890653. eCollection 2022.

DOI:10.3389/fmolb.2022.890653
PMID:36032663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9411646/
Abstract

Omaveloxolone (RTA408) is a second-generation oleanane triterpenoid Nrf2 inducer with antioxidant and anti-inflammatory properties and was reported to improve mitochondrial bioenergetics. It is currently being tested in medical trials for Friedrich ataxia, a genetic, multi-organ disease involving mitochondrial dysfunction. Thus, omaveloxolone could potentially be beneficial for additional disorders involving mitochondrial dysfunction. To this end, we investigated its effect on primary fibroblasts derived from patients with mitochondrial complex I deficiency, mitochondrial cytochrome oxidase deficiency, and two recessive forms of Parkinson's disease. Patients and control cells were incubated in the presence or absence of 50 nM omaveloxolone for 72 h prior to measurements. Generally, growth on galactose medium and ATP production were unaltered. Mitochondrial membrane potential was slightly but significantly decreased, while reactive oxygen species (ROS) production was variably decreased. Mitochondrial mass and mitochondrial DNA (mtDNA) contents were significantly increased in the patient's cells. These results were partially confirmed by the results of oxygen consumption studies which disclosed increased maximal oxygen consumption rates in most cells and increased energy status in all treated cells. Further investigation is required to explore the precise effect of omaveloxolone on mitochondrial function in disease.

摘要

奥马韦洛酮(RTA408)是一种具有抗氧化和抗炎特性的第二代齐墩果烷三萜类Nrf2诱导剂,据报道可改善线粒体生物能量学。目前它正在进行针对弗里德赖希共济失调的医学试验,这是一种涉及线粒体功能障碍的遗传性多器官疾病。因此,奥马韦洛酮可能对其他涉及线粒体功能障碍的疾病有益。为此,我们研究了它对来自线粒体复合物I缺乏症、线粒体细胞色素氧化酶缺乏症患者以及两种隐性帕金森病患者的原代成纤维细胞的影响。在测量前,将患者细胞和对照细胞在有或无50 nM奥马韦洛酮的情况下孵育72小时。一般来说,在半乳糖培养基上的生长和ATP产生未改变。线粒体膜电位略有但显著下降,而活性氧(ROS)产生则有不同程度的下降。患者细胞中的线粒体质量和线粒体DNA(mtDNA)含量显著增加。耗氧研究结果部分证实了这些结果,该研究表明大多数细胞的最大耗氧率增加,所有处理细胞的能量状态增加。需要进一步研究以探索奥马韦洛酮在疾病中对线粒体功能的确切影响。

相似文献

1
Variable effects of omaveloxolone (RTA408) on primary fibroblasts with mitochondrial defects.奥马韦洛酮(RTA408)对具有线粒体缺陷的原代成纤维细胞的可变效应。
Front Mol Biosci. 2022 Aug 12;9:890653. doi: 10.3389/fmolb.2022.890653. eCollection 2022.
2
Novel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich's Ataxia Models.新型Nrf2诱导剂可预防弗里德赖希共济失调模型中的线粒体缺陷和氧化应激。
Front Cell Neurosci. 2018 Jul 17;12:188. doi: 10.3389/fncel.2018.00188. eCollection 2018.
3
Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.新型Nrf2激活剂奥马韦洛酮在灵长类动物中的药代动力学和药效学
Drug Des Devel Ther. 2019 Apr 17;13:1259-1270. doi: 10.2147/DDDT.S193889. eCollection 2019.
4
Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia.奥马伐罗酮治疗弗里德赖希共济失调的安全性、药效学和潜在益处。
Ann Clin Transl Neurol. 2018 Nov 10;6(1):15-26. doi: 10.1002/acn3.660. eCollection 2019 Jan.
5
Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.合成三萜类化合物口服奥伐洛酮(RTA 408)在晚期实体瘤患者首次人体试验中的安全性、药代动力学和药效学。
Onco Targets Ther. 2017 Aug 29;10:4239-4250. doi: 10.2147/OTT.S136992. eCollection 2017.
6
Mitochondrial bioenergetics and dynamics interplay in complex I-deficient fibroblasts.线粒体生物能量学与动力学在复合物I缺陷型成纤维细胞中的相互作用。
Biochim Biophys Acta. 2010 May;1802(5):443-53. doi: 10.1016/j.bbadis.2010.02.001. Epub 2010 Feb 11.
7
Omaveloxolone and TX63682 are hepatoprotective in the STAM mouse model of nonalcoholic steatohepatitis.奥马韦洛酮和TX63682在非酒精性脂肪性肝炎的STAM小鼠模型中具有肝脏保护作用。
J Biochem Mol Toxicol. 2020 Sep;34(9):e22526. doi: 10.1002/jbt.22526. Epub 2020 May 14.
8
Effect of thyroid hormone on mitochondrial properties and oxidative stress in cells from patients with mtDNA defects.甲状腺激素对线粒体DNA缺陷患者细胞中线粒体特性及氧化应激的影响。
Am J Physiol Cell Physiol. 2009 Feb;296(2):C355-62. doi: 10.1152/ajpcell.00415.2007. Epub 2008 Nov 26.
9
Mitochondrial remodeling in human skin fibroblasts from sporadic male Parkinson's disease patients uncovers metabolic and mitochondrial bioenergetic defects.散发性男性帕金森病患者皮肤成纤维细胞中线粒体重构揭示了代谢和线粒体生物能量缺陷。
Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165615. doi: 10.1016/j.bbadis.2019.165615. Epub 2019 Nov 20.
10
Mitochondrial biogenesis: pharmacological approaches.线粒体生物合成:药理学方法。
Curr Pharm Des. 2014;20(35):5507-9. doi: 10.2174/138161282035140911142118.

引用本文的文献

1
Therapeutic potential of NRF2 activating drug RTA-408 in suppressing T cell effector responses and inflammatory bowel disease.NRF2激活药物RTA-408在抑制T细胞效应反应和炎症性肠病方面的治疗潜力。
J Immunol. 2025 Aug 1;214(8):1951-1968. doi: 10.1093/jimmun/vkaf117.
2
Therapeutic potential of omaveloxolone in counteracting muscle atrophy post-denervation: a multi-omics approach.奥马伐洛酮在拮抗失神经后肌肉萎缩中的治疗潜力:多组学方法。
J Transl Med. 2024 Nov 2;22(1):991. doi: 10.1186/s12967-024-05810-7.
3
Clinical Approaches for Mitochondrial Diseases.

本文引用的文献

1
Fighting Parkinson's disease: The return of the mitochondria.对抗帕金森病:线粒体的回归
Mitochondrion. 2022 May;64:34-44. doi: 10.1016/j.mito.2022.02.003. Epub 2022 Feb 24.
2
A Perspective on Nrf2 Signaling Pathway for Neuroinflammation: A Potential Therapeutic Target in Alzheimer's and Parkinson's Diseases.神经炎症的Nrf2信号通路视角:阿尔茨海默病和帕金森病的潜在治疗靶点
Front Cell Neurosci. 2022 Jan 21;15:787258. doi: 10.3389/fncel.2021.787258. eCollection 2021.
3
Targetable Pathways for Alleviating Mitochondrial Dysfunction in Neurodegeneration of Metabolic and Non-Metabolic Diseases.
线粒体疾病的临床方法。
Cells. 2023 Oct 20;12(20):2494. doi: 10.3390/cells12202494.
靶向治疗代谢和非代谢疾病神经退行性变中线粒体功能障碍的相关通路。
Int J Mol Sci. 2021 Oct 23;22(21):11444. doi: 10.3390/ijms222111444.
4
Levodopa-responsive dystonia caused by biallelic exon inversion invisible to exome sequencing.双等位基因外显子倒置导致的左旋多巴反应性肌张力障碍,外显子测序无法检测到。
Brain Commun. 2021 Sep 6;3(3):fcab197. doi: 10.1093/braincomms/fcab197. eCollection 2021.
5
Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).奥马伐洛酮治疗弗里德赖希共济失调(MOXIe 研究)的安全性和疗效。
Ann Neurol. 2021 Feb;89(2):212-225. doi: 10.1002/ana.25934. Epub 2020 Nov 5.
6
Moving towards clinical trials for mitochondrial diseases.迈向线粒体疾病临床试验。
J Inherit Metab Dis. 2021 Jan;44(1):22-41. doi: 10.1002/jimd.12281. Epub 2020 Sep 2.
7
Reader response: Peripheral synucleinopathy in a DJ1 patient with Parkinson disease, cataracts, and hearing loss.读者回应:一名患有帕金森病、白内障和听力损失的DJ1患者的外周α-突触核蛋白病
Neurology. 2020 May 26;94(21):943-944. doi: 10.1212/WNL.0000000000009495.
8
Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia.奥马伐罗酮治疗弗里德赖希共济失调的安全性、药效学和潜在益处。
Ann Clin Transl Neurol. 2018 Nov 10;6(1):15-26. doi: 10.1002/acn3.660. eCollection 2019 Jan.
9
Novel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich's Ataxia Models.新型Nrf2诱导剂可预防弗里德赖希共济失调模型中的线粒体缺陷和氧化应激。
Front Cell Neurosci. 2018 Jul 17;12:188. doi: 10.3389/fncel.2018.00188. eCollection 2018.
10
Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.合成三萜类化合物口服奥伐洛酮(RTA 408)在晚期实体瘤患者首次人体试验中的安全性、药代动力学和药效学。
Onco Targets Ther. 2017 Aug 29;10:4239-4250. doi: 10.2147/OTT.S136992. eCollection 2017.